Medtronic, Inc.

WEST BRIDGEWATER, Mass., Oct. 31, 2024 /PRNewswire/ -- Executive management from Primo Medical Group along with others, combined to acquire Arthrosurface, Inc., a leading provider of joint restoration and preservation solutions for active patients, from Anika Therapeutics (NASDAQ: ANIK). Two former Arthrosurface leaders joined the Primo Medical Group executives in this strategic acquisition which ensures that Arthrosurface's position as a leader in orthopedic joint preservation solutions will resume with its portfolio of innovative products and expertise. Continue Reading arthrosurface company logo Arthrosurface: A Pioneer in Joint Restoration and Preservation Shane Shankle, who was appointed Arthrosurface's new President said, "As a leader in joint preservation, I'm excited to drive our company's growth plan by delivering products that help patients maintain an active quality of life." Frank Fedorowicz, Chief Operating and Financial Officer, added, "I'm very happy to be reunited with many of our founding executives to propel Arthrosurface into its next exciting phase." With a commitment to minimally invasive techniques, Arthrosurface products are designed to restore natural joint function while preserving surrounding bone and tissue. Arthrosurface's product portfolio includes more than 150 different surface implant curvatures for the knee, shoulder, wrist and toe that are designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Andrea Patisteas, Senior Executive Vice President emphasized that "With over two decades of clinical experience with our implants, we're thrilled to continue working with physicians and patients to provide them with options for the treatment of orthopedic conditions." Steven Tallarida, President and CEO of Primo Medical Group simply commented "It is great to be back!" Phoenix Brio will be Arthrosurface's parent company, and both will be based in West Bridgewater, Massachusetts. "The acquisition of Arthrosurface aligns with our mission to create and deliver innovative medical solutions that address today's clinical needs. Arthrosurface is a natural fit for us," said Chris LaPlante, CFO at Primo Medical Group. Customers and distributors of Arthrosurface products should not expect to see any change in service or disruption in product access or availability. About Primo Medical Group Primo Medical Group offers the most comprehensive outsourcing solutions for the medical device market, including OEM product distribution services, engineering services, precision component production, finished goods assembly, medical device refurbishment, reusable surgical kit management and complete supply chain management. Established in 1953, Primo Medical Group is a privately held company with five facilities in Massachusetts. Primo Medical Group is an FDA Registered Contract Manufacturer and is compliant with FDA Quality Systems Regulations. Primo Medical Group is also ISO 13485:2016 certified and is a registered manufacturer with the Office of Defense Trade Controls Compliance. Over the past 24 years Primo Medical Group has incubated and co-funded several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface (acquired by Anika Therapeutics), Spirus Medical, Inc. (acquired by Olympus), Saphena Medical Inc. (acquired by a major strategic in 2024), Cardiosolutions, Inc., Trax Surgical, Inc. and Versago Vascular Access. For media inquiries, please contact: Andrea Patisteas 781-828-4400 [email protected] SOURCE Primo Medical Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

This is the Company's third annual sustainability report, which discloses progress against its environmental, social and governance (ESG) metrics in 2023 BUFFALO GROVE, Ill., Sept. 27, 2024 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), one of the world's largest suppliers of life science buffers and other proprietary ingredients, today released its 2023 Corporate Sustainability Report. This is the Company's third annual public report, which is available through the Advancion website at . The theme of this year's report, "Empowering Impact: Driving Sustainable Progress with Purpose," focuses on the positive contributions Advancion's ingredients and people are making to improve the environment, society and the economy. Advancion's 2023 Sustainability Report highlights the Company's progress against its environmental, social and governance (ESG) targets, including: Overview of the essential ways that Advancion's ingredients and specialized knowledge is enabling and enhancing the performance, efficiency and sustainability of end products and industries critical to modern life. Reduction of Advancion's Total Recordable Case (TRC) injury rate from 0.65 in 2022 to 0.42 in 2023, including zero injuries across the Company's major manufacturing, research and development (R&D), and administrative facilities. Expansion of the Scope 1, Scope 2 and Scope 3 emissions data to include the Sterlington and Ibbenbüren manufacturing facilities, the Buffalo Grove Corporate Office and R&D Center, and the Expression Systems manufacturing and research site in Davis, California. Overall reduction in energy and water consumption, and waste generated during the year, as well as the positive increase in total hazardous waste diverted to beneficial reuse and energy recovery. Updates on the Company's progress in further integrating sustainability into its core business strategy with the launch of new products developed from renewable raw material sources. Reporting prepared in accordance with the GRI Sustainability Reporting Standards 2021, as well as other standards issued by the Sustainability Accounting Standards Board (SASB) and the United Nations Sustainable Development Goals (UN SDGs). "We are proud to share our latest sustainability report, which not only highlights our significant progress but also reflects the core values that guide every decision we make at Advancion," said David Neuberger, President and Chief Executive Officer. "As a leading global producer of specialty ingredients, we recognize our responsibility extends beyond delivering innovative solutions—we must also address the environmental, social and economic challenges of our time. This report underscores our progress and our dedication to driving positive changes across the markets and communities we serve. Our goal is clear: to deliver long-term value for our customers, employees and communities while safeguarding the health of our planet. We remain focused on accountability, transparency and continuous improvement as we work toward a more sustainable future for all our stakeholders." For more information about Advancion's sustainability platform and to download the 2023 Corporate Sustainability Report, visit advancionsciences.com/sustainability. ABOUT ADVANCION Advancion, formerly ANGUS Chemical Company, is a leading global producer of specialty ingredients and consumables for biotechnology, pharmaceuticals, home and personal care, and other consumer-oriented and industrial markets. The Company is one of the world's largest producers of life sciences buffers and other proprietary ingredients, providing high-performance products, best-in-class quality and guaranteed supply security for more than 80 years. Through Expression Systems, an Advancion company, the Company produces innovative cell culture media formulations, cell lines, molecular tools and reagents used in the development and commercial manufacturing of advanced therapies. Advancion operates three manufacturing facilities in the U.S. and Germany and serves its global customers through six regional Customer Application Centers located in Chicago, Illinois; Paris, France; São Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. The Company is privately owned by Ardian and Golden Gate Capital, and is headquartered in Buffalo Grove, Illinois. For more information, visit advancionsciences.com. Follow Advancion on LinkedIn. FOR ADDITIONAL INFORMATION Advancion Media Relations Scott C. Johnson +1 847-808-3769 [email protected] SOURCE Advancion Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics’ proprietary tined lead design and temperature sensor technology is differentiated from our competitor’s intellectual property,” said Raymond W. Cohen, chief executive officer. “As we have said since this case was first filed in late 2019, our view is that Medtronic’s lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent’s monopoly in sacral neuromodulation. We are very pleased with the jury’s finding and continue to remain focused on fulfilling our mission of positively impacting the lives of adults with bladder and bowel dysfunction.” About Axonics Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022 . Axonics ® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid ® , provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary and bowel incontinence affects tens of millions of adults. For more information, visit www.axonics.com . Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like “may,” “will,” “likely,” “should,” “expect,” “anticipate,” “future,” “plan,” “believe,” “intend,” “goal,” “seek,” “endeavor,” “estimate,” “project,” “continue,” and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: Axonics’ ability to consummate the transactions contemplated by the Agreement and Plan of Merger, dated January 8, 2024 (the “Merger Agreement”), by and among Axonics, Boston Scientific Corporation (“Boston Scientific”), and Sadie Merger Sub, Inc., a wholly owned subsidiary of Boston Scientific (“Merger Sub”), providing for the merger of Merger Sub with and into Axonics with Axonics continuing as the surviving company and a wholly owned subsidiary of Boston Scientific (the “Merger”), in a timely manner or at all; the risk that the Merger Agreement may be terminated in circumstances requiring the payment by Axonics of a termination fee; the satisfaction (or waiver) of the conditions to the closing of the Merger; potential delays in consummating the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the Merger Agreement; Axonics’ ability to timely and successfully realize the anticipated benefits of the Merger; the ability to successfully integrate the businesses of Axonics and Boston Scientific; the effect of the announcement or pendency of the Merger on Axonics’ current plans, business relationships, operating results and business generally; the effect of limitations placed on Axonics’ business under the Merger Agreement; significant transaction costs and unknown liabilities; litigation or regulatory actions related to the Merger Agreement or Merger; FDA or other U.S. or foreign regulatory or legal actions or changes affecting Axonics or Axonics’ industry; the results of any ongoing or future legal proceedings, including the litigation with Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (the “Medtronic Litigation”); any termination or loss of intellectual property rights, including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics’ competitors, and the timing of these introductions and announcements; changes in macroeconomic and market conditions and volatility, including the risk of recession, inflation, supply chain constraints or disruptions and rising interest rates; and economic and market conditions in general and in the medical technology industry specifically, including the size and growth, if any, of Axonics’ markets, and risks related to other factors described under “Risk Factors” in other reports and statements filed with the U.S. Securities and Exchange Commission (“SEC”), including Axonics’ most recent Annual Report on Form 10-K, which is available on the investor relations section of Axonics’ website at www.axonics.com and on the SEC’s website at www.sec.gov . Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.